Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

Conditions:   Platinum-Refractory Fallopian Tube Carcinoma;   Platinum-Refractory Ovarian Carcinoma;   Platinum-Refractory Primary Peritoneal Carcinoma;   Recurrent Fallopian Tube Endometrioid Adenocarcinoma;   Recurrent High Grade Fallopian Tube Serous Adenocarcinoma;   Recurrent High Grade Ovar ian Serous Adenocarcinoma;   Recurrent Ovarian Endometrioid Adenocarcinoma;   Recurrent Platinum-Resistant Fallopian Tube Carcinoma;   Recurrent Platinum-Resistant Ovarian Carcinoma;   Recurrent Platinum-Resistant Primary Peritoneal Carcinoma;   Recurrent Primary Peritoneal Endometrioid A denocarcinoma;   Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma Interventions:   Drug: Copanlisib Hydrochloride;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Drug: Topotecan Hydrochloride Sponsors:   National Cancer Institute (NCI);   NRG Oncology Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials